Floatz logo

AZD 3965

Burkitt Lymphoma

Cancer Research UKSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

74 Active assets in the Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 4BBB
VINCRISTINE SULFATE
AIDS Malignancy Consortium
Phase 2BBB
VINDESINE
PETHEMA Foundation
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 4BBB

View all 50 →

Same molecule, other indications

AZD 3965 is also rated in:

Adult Solid TumorDormant
CC
Indicative ·
44 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →